{"entity":{"id":"nct07069595","kind":"trial","name":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","aka":["PREDICT-RD"],"tldr":"A phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.","summary":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease. ClinicalTrials.gov record last updated 2026-04-22: recruiting. Enrollment is planned at 78 participants. Primary completion is estimated at 2031-11-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Datopotamab deruxtecan, Circulating tumor DNA (ctDNA) testing. Registered primary measures: The proportion of triple negative breast cancer (TNBC) with molecular residual disease (MRD).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07069595","url":"https://clinicaltrials.gov/study/NCT07069595"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["adc"],"targets":["trop2"],"drugs":["datopotamab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-04-22: recruiting. Enrollment is planned at 78 participants. Primary completion is estimated at 2031-11-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT07069595","phase":"2","setting":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","sponsor":"UNC Lineberger Comprehensive Cancer Center","participation":[{"nct":"NCT07069595","source":"https://clinicaltrials.gov/study/NCT07069595","fetchedAt":"2026-10-07T16:55:23.338Z","studySha256":"04b76dbdc16ea3ff23f8d9cb45a95d74abb7091a692555eb208350edfde0bde7","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-22","leadSponsor":"UNC Lineberger Comprehensive Cancer Center","collaboratorCount":2,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":78,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["United States"]}],"started":"2026-02-26","startedType":"actual","enrolled":78,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07069595/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}